Correlation of mTOR and MRP1 Expression in Patients with Diffuse Large B-cell Lymphoma

JIA Cundong; LI Xiaobo; LI Yanhong; LIANG Liping; BAI Jingping

doi:10.3971/j.issn.1000-8578.2015.09.009

Cancer Research on Prevention and Treatment > 2015 > 42(09): 900-904. > DOI: 10.3971/j.issn.1000-8578.2015.09.009

JIA Cundong, LI Xiaobo, LI Yanhong, LIANG Liping, BAI Jingping. Correlation of mTOR and MRP1 Expression in Patients with Diffuse Large B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(09): 900-904. DOI: 10.3971/j.issn.1000-8578.2015.09.009

Citation:

PDF (2193 KB)

Correlation of mTOR and MRP1 Expression in Patients with Diffuse Large B-cell Lymphoma

1.Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University,Urumqi 830011, China; 2. Xinjiang Technical Institute of Physics&Chemistry, Chinese Academy of Sciences, Urumqi 830011, China; 3. Department of Pathology, Affiliated Tumor Hospital,Xinjiang Medical University, Urumqi 830011, China; 4. Department of Bone Oncology, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi 830011, China

More Information

Received Date: September 18, 2014
Revised Date: January 22, 2015

Graphical Abstract

Abstract

Abstract

Objective To investigate the expression and significance of the mammalian target of rapamycin(mTOR) and multidrug resistance protein 1(MRP1)gene in patients with diffuse large B-cell lymphoma(DLBCL). Methods A total of 109 patients with DLBCL diagnosed from Jan., 2010 to Jun., 2013 were collected from the Affiliated Tumor Hospital, Xinjiang Medical University. The expression of phosphorylated mTOR(p-mTOR) protein and MRP1 mRNA were examined by Western blot and RT-PCR, respectively. Kaplan-Meier method was used for survival analysis. Results The expression of p-mTOR and MRP1 mRNA were 58.7% and 56.9%, respectively(P=0.003). The expression of p-mTOR and MRP1 mRNA in non-germinal center B-cell like(non-GCB) subgroups were significantly higher than those in GCB subgroups(P<0.05). At a median follow-up of 18 months (range 2-52 months), the 3-year progression-free survival (PFS) of patients with positive and negative p-mTOR expression were 23% and 69%(P=0.003). The 3-year PFS of patients with positive and negative MRP1 expression were 39% and 62%(P=0.042). Conclusion Activation of mTOR signaling pathway and MRP1 overexpression play important roles in the development of DLBCL, moreover, MRP1 expression is closely related to mTOR expression.
- Diffuse large B-cell lymphoma,
- Mammalian target of rapamycin(mTOR),
- Multidrug resistance protein 1(MRP1)

FullText(HTML)

References (13)

References

[1]	Yagi K, Yamamoto K, Umeda S, et al. Expression of multidrug resistance 1 gene in B-cell lymphomas: association with follicular dendritic cells[J]. Histopathology, 2013, 62(3): 414-20.
[2]	Maxwell SA, Cherry EM, Bayless KJ. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2011, 52(5): 849-64.
[3]	Witzens-Harig M, Memmer ML, Dreyling M, et al. A phase Ⅰ/Ⅱ trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma-the STORM trial[J]. BMC Cancer, 2013, 13: 308.
[4]	Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy[J]. Clin Cancer Res, 2009, 15(17): 54 94-502.
[5]	Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma[J]. South Asian J Cancer, 2014, 3(1): 66 -70.
[6]	Rocha Gda G, Oliveira RR, Kaplan MA, et al. 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity[J]. Eur J Pharmacol, 2014, 741: 140-9.
[7]	Cai B, Miao Y, Liu Y, et al. Nuclear multidrug-resistance related protein 1 contributes to multidrug-resistance of mucoepidermoid carcinoma mainly via regulating multidrug-resistance protein 1: a human mucoepidermoid carcinoma cells model and Spearman‘s rank correlation analysis[J]. PLoS One, 2013, 8(8): e69611.
[8]	Ohsawa M, Ikura Y, Fukushima H, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma[J]. Oncology, 2005, 68(4-6): 42 2-31.
[9]	Fang C, Xu W, Li JY. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma[J]. Ann Hematol, 2010, 89(11): 1107-13.
[10]	Thieblemont C, Briere J, Mounier N, et al. The germinal center/ activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study[J]. J Clin Oncol, 2011, 29 (31): 4079-87.
[11]	Yu BH, Zhou XY, Xiao XY, et al. Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma[J]. Zhonghua Bing Li Xue Za Zhi, 2009, 38(1): 35 -41. [于宝华, 周晓燕, 肖秀英, 等. AKT/mTOR通路在弥漫性大B细胞淋巴瘤中的活化及其与临床病理相关性的研究[J]. 中华病理学杂志, 2009, 38(1): 35-41.]
[12]	Zang C, Eucker J, Liu H, et al. Concurrent inhibition of PI3- kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1[J]. Cancer Lett, 2013, 339(2): 288-97.
[13]	Jiang XJ, Meng FY, Huang KK, et al. Effect of RAD001 or plus LBH589 on the proliferation, apoptosis and drug resistance in chemoresistant acute myeloid leukemic cells[J]. Zhonghua Yi Xue Za Zhi, 2011, 91(32): 2287-92. [江雪杰, 孟凡义, 黄凯凯, 等. 依维莫司和LBH589对耐药急性髓系白血病细胞增殖、凋亡及多药耐药相关蛋白表达的影响[J]. 中华医学杂志, 2011, 91 (32): 2287-92.]

[1]	LIU Xudong, ZHAO Bin, DU Peng, ZHANG Guoqiang, ZHENG Qiang, LAI Jiamin, CHENG Zhibin. Prognostic Model Based on Preoperative FAR and SII Versus TNM Staging System in Evaluating Prognosis of Patients with Pancreatic Cancer After Radical Resection[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 264-270. DOI: 10.3971/j.issn.1000-8578.2023.22.1090
[2]	ZHU Haiyan, DAI Min, XIAO Mingjia. Clinical Characteristics and Prognosis of AJCC 8^th Edition Stage Ⅲ Gallbladder Cancer with Different Subtypes: A Study Based on SEER Database[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 60-65. DOI: 10.3971/j.issn.1000-8578.2021.20.0190
[3]	ZHANG Yong, BI Jianping, PI Guoliang, ZENG Fanyu, HAN Guang, HU Desheng. An Interpretation of Revised Version of International Association for Study of Lung Cancer for Forthcoming 8th Edition of TNM Classification for Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 313-318. DOI: 10.3971/j.issn.1000-8578.2016.04.016
[4]	LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
[5]	LI Juan, ZHU Shuchai, LIU Zhikun, SU Jingwei, SHEN Wenbin. Correlation between GTV-T Volume, Clinical Stage and Prognosis of Esophageal Carcinoma Patients Treated with Three-dimensional Conformal Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2015, 42(07): 693-696. DOI: 10.3971/j.issn.1000-8578.2015.07.011
[6]	YANG Jingwen, ZHANG Qinghuai, LIU Tong. Comparative Analysis of Colorectal Cancer TNM Staging of American Joint Committee on Cancer 5th ed., 6th ed. and 7th ed.[J]. Cancer Research on Prevention and Treatment, 2013, 40(05): 468-472. DOI: 10.3971/j.issn.1000-8578.2013.05.014
[7]	ZHANG Guangyu, TIAN Xiaolin, ZHONG Li, DAI Ling, ZHU Xijia, JIANG Zhiqing. Clinical Significance of microRNA-93 Expression in Gastric Tumor[J]. Cancer Research on Prevention and Treatment, 2013, 40(05): 447-450. DOI: 10.3971/j.issn.1000-8578.2013.05.009
[8]	WU Zhi-yong, YU Jun-cai, FAN Yang-hang, HUANG Jian-hao, LI En-min. Impact of Lymph Node Ratio on Prognosis of Patients with Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(07): 790-794. DOI: 10.3971/j.issn.1000-8578.2010.07.015
[9]	XIONG Hua, YUAN Xiang-lin, ZOU Yan-mei, YU Shi-ying. Clinical Value of Presurgical Computed Tomography in Diagnosis of TNM Staging of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(08): 682-686. DOI: 10.3971/j.issn.1000-8578.2009.08.015
[10]	WANG Jian-liu, Fu Qi, et al, . Treatment and Prognosis of Endometrial Carcinoma in Advanced Stage[J]. Cancer Research on Prevention and Treatment, 2001, 28(03): 214-216. DOI: 10.3971/j.issn.1000-8578.2150

Cited By

Get Citation

PDF

XML

Article views (1367) PDF downloads (246)

Turn off MathJax

Article Contents

Abstract

References

Correlation of mTOR and MRP1 Expression in Patients with Diffuse Large B-cell Lymphoma

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Correlation of mTOR and MRP1 Expression in Patients with Diffuse Large B-cell Lymphoma

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content